PT  - JOURNAL ARTICLE
AU  - Zhang, Luhao
AU  - Li, Rong
AU  - Song, Gang
AU  - Scholes, Gregory D.
AU  - She, Zhen-Su
TI  - Impairment of T cells’ antiviral and anti-inflammation immunities dominates death from COVID-19
AID  - 10.1101/2021.04.26.21256093
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.26.21256093
4099  - http://medrxiv.org/content/early/2021/08/12/2021.04.26.21256093.short
4100  - http://medrxiv.org/content/early/2021/08/12/2021.04.26.21256093.full
AB  - Clarifying dominant factors determining the immune heterogeneity from non-survivors to survivors is crucial for developing therapeutics and vaccines against COVID-19. The main difficulty is quantitatively analyzing the multi-level clinical data, including viral dynamics, immune response, and tissue damages. Here, we adopt a top-down modelling approach to quantify key functional aspects and their dynamical interplay in the battle between the virus and the immune system, yielding an accurate description of real-time clinical data involving hundreds of patients for the first time. The quantification of antiviral responses demonstrates that, compared to antibodies, T cells play a more dominant role in virus clearance, especially for mild patients (96.5%). Moreover, the anti-inflammatory responses, namely the cytokine inhibition and tissue repair rates, also positively correlate with T cell number and are significantly suppressed in non-survivors. Simulations show that the lack of T cells leads to more significant inflammation, proposing an explanation for the monotonous increase of COVID-19 mortality with age and higher mortality for males. We conclude that T cells play a crucial role in the immunity against COVID-19, which reveals a new direction——improvement of T cell number for advancing current prevention and treatment.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialWe used published data for study. We do not perform our own clinical trialFunding StatementThe research is funded by the W.M. Keck Foundation through award no. 1005586. The authors acknowledge Prof. Kelvin To for sharing data, and Xiaoquan Wang, Guanghui She for discussion.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a theoretical work anaylizing clincal data that published previously so the ethical didelines are followed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the codes to produce figures in our manuscript can be accessed using the following link https://github.com/luhaozhang/covid19.git